/
HIND
$2.13-$0.03 (-1.39%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$15.2M
7M shares
52-week range
$1.75 – $16.00
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
14.81%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-11.87
Vyome Holdings, Inc. Common Stock
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
vyometx.com- Employees
- 18
- IPO / List date
- Aug 15, 2025
- HQ
- SAN CLEMENTE, CA
Held by traders on TradeandTell
No one on the platform currently holds HIND.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in HIND as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded HIND yet.
